Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma - Summary - MDSpire

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

  • By

  • Ming Yao

  • Xavier Cheng-Hong Tsai

  • Chung-Wu Lin

  • Shu-Lang Liao

  • Cheng-Ping Wang

  • Wei-Li Ma

  • Yi-Hsuan Wei

  • Hsiao-Wei Lee

  • Jyh-Ming Liou

  • Wei-Li Chen

  • I-Jong Wang

  • Ann-Lii Cheng

  • Sung-Hsin Kuo

  • May 29, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of frontline Helicobacter pylori eradication (HPE) treatment in patients with early-stage extragastric MALT lymphoma.

Key Findings:
  • Overall response rate (ORR) was 65.4%, with 38.5% achieving complete remission (CR) and 26.9% achieving partial remission (PR).
  • Median time to CR was 6 months, with a median duration of lymphoma-free survival of 78.8 months for CR patients.
  • 7-year event-free survival rate was 76.5%, and overall survival rate was 95.8%.
Interpretation:

Limitations:
  • Small sample size of 26 patients limits generalizability.
  • Lack of differentiation between active and past HP infection in serology tests.
Conclusion:

Original Source(s)

Related Content